Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Ulcerative Colitis -- KOL Insight 2019

Product Code:
596201311
Publication Date:
July 2019
Format:
PDF + PPTX

Ulcerative Colitis -- KOL Insight

  • What formulation developments could further drive wider use of Takeda's Entyvio?
  • What safety concerns do KOLs see as hampering the progress of Pfizer's Xeljanz (tofacitinib) and what data might change their opinion?
  • The oral dosing of Celgene's ozanimod is attractive, so why do KOLs believe its challenge to JAK inhibitors or Entyvio will be limited?
  • Despite Roche's etrolizumab's dual targeting and promise of a companion diagnostic KOLs are sceptical about its prospects. Why?

Examples of Therapies Covered

Keytruda bintrafusp alfa (M7824)
Opdivo canakinumab (ACZ885)
Tecentriq TAK 788
Imfinzi AMG 510
Tagrisso (osimertinib) MRTX849
Vizimpro (dacomitinib) tepotinib
Alecensa (alectinib) Capmatinib
Alunbrig (brigatinib) savolitinib (AZD6094)
Lorbrena [US]/Lorviqua [EU] (lorlatinib) selpercatinib (LOXO-292)

Partial List of Participating KOLs

  • Professor of Medicine
    Division of Gastroenterology at Mayo Clinic College of Medicine, Rochester, MN,USA
  • Clinical Gastroenterologist and Professor of Medicine Associate Professor, MD
    Schulich School of Medicine and Dentistry, University of Western Ontario, Canada
  • Professor of Medicine
    University of North Carolina, Chapel Hill, NC, USA
  • Gastroenterologist and Professor of Medicine
    Bologna University, Italy
  • Professor of Gastroenterology
    Université Paris Sud, France
  • Consultant Physician and Gastroenterologist
    Chelsea and Westminster Hospital, London, UK
Therapy Trends reports give you an edge by delivering actionable intelligence to help you make informed decisions about your product. Based entirely on in-depth interviews with the world's foremost KOLs, Therapy Trends research focuses on the major battlegrounds for market share and answers critical business questions about product positioning and competitiveness.
I want an edge. Let's talk
FirstWord PerspectivesWe engage the world's leading key opinion leaders, ensuring the viewpoints delivered are authoritative and consequential. Strict screening criteria ensures high-quality interviews.
FirstWord PerspectivesOur-in house senior analysts and medics leverage their disease area knowledge and market research expertise to identify the key questions and issues.
FirstWord PerspectivesOur reports provide a detailed analysis, based on the candid views of world-renowned KOLs, of how treatment algorithms are likely to evolve over the next 3-5 years.
Continuous Monitoring
Our analysts continually monitor the market and re-engage KOLs throughout the year, delivering event-driven KOL insights on the impact of market changing events such as new clinical trials, pivotal trial results, drug approvals, drug launches and safety alerts.
Boardroom Ready
Short on time? All reports are supported by a convenient slide pack summarising the core of the analysis, making it easy to share with key stakeholders.
Future Driven
Our reports cover the pipeline products that will shape the future, helping you uncover where threats and opportunites will emerge.
Deep Dive
Extensive KOL interviews result in hundreds of direct KOL quotes, providing you with an unbiased and comprehensive view of key market-shaping issues.
Contact Us
First Name*
Last Name*
Email*
Job Title*
Phone*
Company Name
Country Name *
Company
Job Function
Clean_Company
World_Region
FW_Sub_Type
ProductName
Brand_Name
Account Owner
Account_Type
Lead_Type
Product_Code
UID



customer.service@firstwordpharma.com

All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved